Cardio Diagnostics Holdings (NASDAQ: CDIO) is advancing the use of epigenetics to identify hidden risks for heart disease, moving beyond conventional assessments that rely heavily on family history and genetic sequence. The company's diagnostic platform analyzes epigenetic markers—chemical modifications that regulate gene activity without altering the DNA code—to provide a more comprehensive view of an individual's cardiovascular health.
Epigenetics examines how genes are turned on or off in response to lifestyle, behavior, and environmental factors. Unlike static DNA sequences, epigenetic patterns can change over time, reflecting current health status and potential disease risks. Cardio Diagnostics' tests aim to detect these dynamic changes, offering insights that may not be apparent from genetic testing alone. According to the company, this approach can reveal risks that might otherwise go unnoticed until a cardiac event occurs.
CEO of Cardio Diagnostics emphasized that epigenetics not only identifies problems but also suggests potential solutions. By understanding which genes are being expressed or silenced, clinicians can recommend targeted interventions—such as diet modifications, exercise, or medication—to modify those epigenetic patterns and potentially reduce risk.
The company's technology targets a significant gap in cardiovascular care: many individuals who suffer heart attacks have no prior symptoms or traditional risk factors. Epigenetic testing could help identify these seemingly low-risk individuals who actually harbor hidden dangers. Cardio Diagnostics' platform is designed for easy integration into routine clinical practice, using a simple blood sample or other non-invasive methods.
For more information on Cardio Diagnostics and its epigenetic testing, visit the company's newsroom at https://ibn.fm/CDIO. The company’s forward-looking statements and disclaimers are available at http://IBN.fm/Disclaimer.
